New guidance means millions of people will get access to medicines that protect the heart and kidneys, while NHS savings of £560 million from using generic dapagliflozin can be reinvested elsewhere in NHS care.
Nice has recommended the first disease modifying treatment for arginase 1 deficiency (ARG1-D), an ultra-rare, inherited and progressive metabolic disorder, for routine use in the NHS in England.
People across England and Wales are set to receive faster, fairer access to innovative HealthTech under the new National HealthTech Access Programme (NHAP).
A wireless sensor the size of a paperclip could transform care for people living with chronic heart failure, enabling them to monitor their condition daily from home and catch warning signs before they become emergencies, NICE has said.
As Sam Roberts prepared to hand over the baton as chief executive, she reflected on her time at NICE and looked to the next chapter for the organisation. She also reflected on our 2025 highlights and achievements in delivering our transformation plan and our commitments in the 10 Year Plan.
NICE is poised to deliver key commitments in the government’s 10 Year Plan for health and care. We’re delighted by the plan’s endorsement of our role in delivering faster, and fairer access to the best innovations. It will strengthen our position in the system, guided by our core purpose.
Understand why we're prioritising key topic areas for evaluation and what it means for innovators
Our associate director of NICE Advice outlines his top tips for healthtech companies, helping them chart a clear path from innovation to NHS adoption.
